SCHEMBL6260980

SCHEMBL6260980

COc1cc(OC)cc(N2CCN(C(=O)c3cc(CO)nn3-c3ccccc3)CC2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.53
MAPT P10636 2/20 0.48
TP53 P04637 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NPC1 O15118 1/20 0.48
POLB P06746 1/20 0.48
RAB9A P51151 1/20 0.48
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
LMNA P02545 2/20 0.44
MEN1 O00255 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
GAA P10253 2/20 0.44
MGLL Q99685 1/20 0.43
DRD2 P14416 1/20 0.43
HTR2A P28223 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6260030 0.91 KMT2A (0.53) KMT2AMAPTTP53SMN1; SMN2NPC1
SCHEMBL6260022 0.88 KMT2A (0.50) KMT2AMAPTTP53SMN1; SMN2NPC1
SCHEMBL6414102 0.88 KMT2A (0.52) KMT2AMAPTTP53SMN1; SMN2NPC1
SCHEMBL6413083 0.88 KMT2A (0.50) KMT2AMAPTTP53SMN1; SMN2NPC1
SCHEMBL6416498 0.86 KMT2A (0.48) KMT2AMAPTTP53SMN1; SMN2NPC1
SCHEMBL6265709 0.86 KMT2A (0.59) KMT2AMAPTTP53SMN1; SMN2NPC1
SCHEMBL6264678 0.85 KMT2A (0.48) KMT2AMAPTTP53SMN1; SMN2NPC1
SCHEMBL6260121 0.85 KMT2A (0.55) KMT2AMAPTTP53SMN1; SMN2NPC1
SCHEMBL6263564 0.85 KMT2A (0.55) KMT2AMAPTTP53SMN1; SMN2NPC1
SCHEMBL6421180 0.85 KMT2A (0.47) KMT2AMAPTTP53SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590329-A1 N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2005-11-02 EP disclosed
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AVENTIS PHARMA S. A. (FR) 2005-06-16 US disclosed
WO-2004078732-A1 N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AHR, NQO1, ARNT KMT2A 1284/4885MAPT 4098/4885TP53 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.